ANDA 71153, held by Astrazeneca. Bretylium Tosylate.
As of Nov 16, 2026, ANDA 71153 (Bretylium Tosylate), held by Astrazeneca, was not approved, with 0 approved supplements and 0 published complete response letters.
| Product | Active ingredient | Marketing |
|---|---|---|
| Bretylium Tosylate50MG/ML ยท injectable;injection | Bretylium Tosylate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters